LONDON (ShareCast) - (Sharecast News) - Astrazeneca and Merck said their Lynparza prostate cancer treatment had met a second goal in a trial for patients suffering from the metastatic castration-resistant version of the disease.
Astrazeneca said on Friday that results from the PROfound trial showed a "statistically significant and clinically meaningful improvement" in the key secondary endpoint of overall survival after having met its primmer endpoint in August 2019.

The FTSE 100-listed group also noted that the safety and tolerability profile of Lynparza was generally consistent with previous trials.

José Baselga, Astrazeneca's Vice President of Oncology, said: "Overall survival in metastatic castration-resistant prostate cancer has remained extremely challenging to achieve."

As of 0825 BST, AZN shares were down 0.66% at 8,133p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE